Expert Review Of ImClone Protocol Concludes C225 Approval Unlikely.
Retrospective Data Clean-Up Can’t Help C225 Phase II Trial; Protocol Far Too “Fuzzy”.
ImClone Protocol Generates More Questions Than Answers.
Phase III Trial Would Give Clearer Picture Of C225 Role.
Thomas Jordan To Help ASCO Enhance International Relations, Retires From BMS.
Levine Leaves Presidency Of Rockefeller University.
Trending Stories
- Lou Weiner: Poetry and art help us imagine my mother’s world as a hidden child of the Holocaust
- ACOG says it will no longer accept federal funding
- Knight Cancer Institute receives record-setting $2B gift from the Knights—and self-governance within OHSU
Brian Druker returns to executive role as president of the new Knight Cancer Group - When public service ends abruptly, do books provide solace? An escape? Perspective?
Former NIH and FDA employees tell us what they are reading in 2025 - Andrea Werblin Reid’s unflinching poetry documents the realities of cancer care, clinical trials, and loss
Her collection, “To See Yourself As You Vanish,” will be published three years after her death - The Directors: Mary Beckerle and Neli Ulrich on delivering cancer care across five states
Honoring the Jon Huntsman Sr. political perspective: “I’m not a member of any party except the Cancer Party”
